Kwality targets FY29 revenue above Rs 1,000 crore and margin above 30%

Kwality targets revenue above Rs 1,000 crore and an earnings before interest, tax, depreciation and amortisation (EBITDA) margin above 30% by FY29, versus an approximately 24% FY26 EBITDA margin. Management’s roadmap cites approximately Rs 260 crore of capital expenditure, specialty products, regulated-market filings and export-led margin stability as the supporting levers.

What is Kwality's FY29 revenue and margin target?

Kwality’s FY29 target is revenue of more than Rs 1,000 crore and an EBITDA margin of more than 30%. The presentation’s qualitative margin waterfall begins with an FY26 EBITDA margin of approximately 24% and identifies product mix, operating leverage, higher filings, exports, research and development, and complex products as routes to the FY29 target.

The FY29 ambition follows a nearer-term FY27E revenue target of more than Rs 720 crore, with EBITDA of about Rs 189 crore to Rs 196 crore, an EBITDA margin of 27% to 28%, and profit after tax (PAT) of Rs 122 crore. Management presents FY27 as an intermediate milestone before the FY29 revenue and margin objectives.

Kwality’s reported revenue from operations rose from Rs 370 crore in FY25 to Rs 503 crore in FY26, while EBITDA increased from Rs 80 crore to Rs 118 crore. The roadmap therefore requires revenue to rise beyond the FY26 level of Rs 503 crore while the stated margin benchmark increases by more than 6 percentage points from approximately 24% to above 30%.

What does the FY27 milestone imply for Kwality?

Kwality’s FY27E plan calls for revenue of more than Rs 720 crore, at least Rs 217 crore above FY26 reported revenue of Rs 503 crore. Management forecasts FY27 EBITDA of about Rs 189 crore to Rs 196 crore, compared with reported EBITDA of Rs 118 crore in FY26.

The planned FY27 margin range of 27% to 28% is linked to a stated 300-basis-point increase from 25% to about 28%; one basis point equals one-hundredth of a percentage point. Management connects this expansion to commercialising Erythropoietin, its first biologic, in the first half of the next financial year, alongside complex and niche injectable manufacturing.

Kwality’s operating data show a shorter cash cycle during the reported growth period. Cash conversion days declined from 297 in FY23 to 161 in FY26 and 130 in H1FY27, while inventory days fell from 232 to 114 and then 77 over the same periods. Return on equity rose from 11% in FY24 to 28.4% in H1FY27, while return on capital employed was 31.0% in both FY26 and H1FY27.

How does Kwality plan to lift EBITDA margin above 30%?

Kwality plans to support the FY29 margin target through better product mix, operating leverage, higher filings and export-led margin stability, alongside investment in research and development and complex products. The presentation associates these levers with approximately Rs 260 crore of capital expenditure, without providing a year-by-year allocation.

Capacity expansion is focused on oncology, biologics and hormone products, with new formulation development through bio-equivalence (BE) studies. Kwality also plans to expand monoclonal-antibody capabilities, which are included in the capital-expenditure programme underlying the FY29 margin waterfall.

Operational efficiency is another stated lever. Kwality has completed more than 10 secondary-packaging technology-transfer projects in international markets, which management says are intended to optimise logistics and local-compliance costs and enable faster market entry. The presentation does not quantify savings from the projects or their separate contribution to EBITDA.

What supports Kwality's regulated-market and export plan?

Kwality has European Union Good Manufacturing Practice (EU-GMP) approval at four of its five manufacturing plants and reports more than 40 BE programmes covering more than 40 molecules for highly regulated markets. Management presents these capabilities as support for widening global reach and building trust in regulated markets.

The regulated-market programme combines the 40-plus molecule pipeline with secondary-packaging transfers in international markets. The more than 10 completed transfers are designed to address logistics and local-compliance requirements, while the EU-GMP footprint is intended to support market access for products developed through BE studies.

The presentation identifies higher filings and export-led margin stability as FY29 drivers, but does not disclose an export-revenue target, a country-level launch schedule or expected approval dates for the BE programmes. The disclosed evidence is four EU-GMP-approved plants, more than 40 programmes and more than 10 completed packaging transfers, rather than quantified overseas sales guidance.

Conclusion

Kwality’s roadmap combines a FY27E target of more than Rs 720 crore in revenue and a 27% to 28% EBITDA margin with a FY29 objective of more than Rs 1,000 crore and margin above 30%. Reported FY26 revenue of Rs 503 crore, EBITDA of Rs 118 crore and PAT of Rs 67 crore provide the financial base from which management proposes this expansion.

The next disclosed execution point is commercialisation of Erythropoietin in the first half of the next financial year, alongside capacity expansion in oncology, biologics, hormones and monoclonal antibodies. Progress against the approximately Rs 260 crore capital-expenditure plan, the more than 40 BE programmes and the FY27E revenue and margin targets will indicate whether the FY29 plan is advancing as management envisages.